Docetaxel
Refractory Cancer
Washington University School of MedicineSmall moleculePhase 1Dormant
CC
46/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 37/ 100
- Competitive Position
- 73/ 100
Competitive context
45 Active assets in the Refractory Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Eloxatin M.D. Anderson Cancer Center | Phase 2 | B |
Tocilizumab University Health Network, Toronto | Phase 4 | B |
Pembrolizumab GV20 Therapeutics | Phase 2 | B |
Cyclophosphamide National Cancer Institute (NCI) | Phase 2 | B |
Irinotecan Children's Oncology Group | Phase 2 | B |
View all 50 →
Same molecule, other indications
Docetaxel is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →